Effects of a 12‐Week Mediterranean‐Type Time‐Restricted Feeding Protocol in Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Randomised Controlled Trial—The ‘ CHRONO ‐ NAFLD Project’
Alimentary Pharmacology & Therapeutics · 2025
DOI: 10.1111/apt.70044 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2025. Verfasst von Sofia Tsitsou und 7 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Dietetics and Quality of Life, Department of Food Science and Human Nutrition, Agricultural University of Athens, Athens, Greece. Hauptthemen laut MEDLINE: Diet, Mediterranean, Non-alcoholic Fatty Liver Disease, Obesity, Intermittent Fasting. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
The Mediterranean diet (MD) is considered the best dietary approach for patients with metabolic dysfunction‐associated steatotic liver disease (MASLD). Recently, time‐restricted feeding (TRF) has gained attention for its lifestyle compatibility and health benefits.
Aims
This study aimed to compare the effects of a hypocaloric MD with a 10‐h TRF protocol to an unrestricted MD in MASLD patients with overweight/obesity and evaluate differences between early and late TRF.
Methods
This 12‐week randomised controlled trial in MASLD patients with overweight/obesity consisted of three groups, all following a hypocaloric Mediterranean‐type diet. The control group had no eating time restrictions. The early TRF (eTRF) and late TRF (lTRF) groups had a 10‐h eating window, from 8 AM to 6 PM and from 12 PM to 10 PM, respectively. Various health parameters were measured. Compliance was tracked via food diaries, and an 8‐week follow‐up occurred post‐intervention.
Results
Fifty‐nine MASLD individuals (27 males; 52.9 years; body mass index 32.1 kg/m 2 ) completed the trial (control, n = 19; eTRF, n = 20; lTRF, n = 20). All groups showed significant 12‐week reductions in body weight, anthropometry and blood pressure. Glycated haemoglobin A 1c and insulin resistance, as measured by the Matsuda index, homeostatic model assessment for insulin resistance and fasting glucose‐to‐insulin ratio, improved in the eTRF group at 12 weeks.
Conclusions
This study corroborates the efficacy of MD in ameliorating cardiometabolic risk factors such as body weight and blood pressure in MASLD patients. The combination with an eTRF protocol may improve glycaemic control (NCT05866744). Trial Registration The study is registered at clinicaltrials.gov (NCT05866744)
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Laboratory of Dietetics and Quality of Life, Department of Food Science and Human Nutrition, Agricultural University of Athens, Athens, Greece.
- First Department of Internal Medicine, Laiko General Hospital of Athens, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
- Fourth Department of Internal Medicine, Attiko University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
ORCID-Profile: Sofia Tsitsou, Kalliopi-Anna Poulia, Dimitrios S Karagiannakis, Emilia Papakonstantinou, Evangelos Cholongitas
Zitieren
APA
Tsitsou, S., Bali, T., Adamantou, M., Saridaki, A., Poulia, K. A., Karagiannakis, D. S., Papakonstantinou, E., & Cholongitas, E. (2025). Effects of a 12‐Week Mediterranean‐Type Time‐Restricted Feeding Protocol in Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Randomised Controlled Trial—The ‘ CHRONO ‐ NAFLD Project’. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70044
Vancouver
Tsitsou S, Bali T, Adamantou M, Saridaki A, Poulia KA, Karagiannakis DS, et al. Effects of a 12‐Week Mediterranean‐Type Time‐Restricted Feeding Protocol in Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Randomised Controlled Trial—The ‘ CHRONO ‐ NAFLD Project’. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.70044
BibTeX
@article{Tsitsou2025,
author = {Tsitsou, Sofia and Bali, Triada and Adamantou, Magdalini and Saridaki, Aristi and Poulia, Kalliopi-Anna and Karagiannakis, Dimitrios S and Papakonstantinou, Emilia and Cholongitas, Evangelos},
title = {Effects of a 12‐Week Mediterranean‐Type Time‐Restricted Feeding Protocol in Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Randomised Controlled Trial—The ‘ CHRONO ‐ NAFLD Project’},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2025},
doi = {10.1111/apt.70044}
}
EUVIMED